
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Catalyst Total Tracker
Data & Risk Disclaimer
Data source. All entries in this tracker are compiled from public and third-party sources (company press releases, FDA/EMA calendars, clinicaltrials.gov, SEC filings and market data providers).
Accuracy. Despite best efforts, dates, tickers, catalyst descriptions and other fields may be delayed, incomplete, approximate or contain errors. Events can be rescheduled, cancelled or updated without notice by the issuing companies or regulators.
Use of this tool. This tracker is provided for educational and informational purposes only. It is not a real-time official calendar and must not be relied upon as a single source for trading or investment decisions.
Independent verification. Always verify each catalyst and date directly on official sources (company IR, SEC/Consob filings, FDA/EMA websites, clinicaltrials.gov and primary regulatory communications) before acting.
No investment advice. Nothing shown in this tracker constitutes investment advice, financial promotion or a recommendation to buy or sell any security. Users remain solely responsible for their decisions and for complying with the laws and regulations of their jurisdiction.
Origine dei dati. Tutte le voci di questo tracker sono raccolte da fonti pubbliche e terze parti (comunicati stampa societari, calendari FDA/EMA, clinicaltrials.gov, documenti SEC e fornitori di dati di mercato).
Accuratezza. Nonostante l’attenzione nella compilazione, date, ticker, descrizioni dei catalyst e altri campi possono essere in ritardo, incompleti, approssimativi o contenere errori. Gli eventi possono essere riprogrammati, annullati o modificati senza preavviso dalle società o dalle autorità.
Uso di questo strumento. Il tracker è fornito esclusivamente a scopo informativo ed educativo. Non rappresenta un calendario ufficiale in tempo reale e non deve essere utilizzato come unica base per decisioni di trading o investimento.
Verifiche indipendenti. Verifica sempre ogni catalyst e ogni data direttamente sulle fonti ufficiali (sito IR della società, documenti SEC/Consob, siti FDA/EMA, clinicaltrials.gov e comunicazioni regolatorie primarie) prima di agire.
Nessuna raccomandazione. Nulla di quanto riportato in questo tracker costituisce consulenza finanziaria, sollecitazione al pubblico risparmio o raccomandazione all’acquisto o vendita di strumenti finanziari. L’utente rimane l’unico responsabile delle proprie decisioni e del rispetto delle norme vigenti nel proprio ordinamento.
Biotech catalysts by month
The tracker above lists every catalyst Merlintrader follows. For a readable list of a single month, with FDA decisions, expected clinical data, medical congresses and investor events in separate tables and a link to the primary source for each event, open the monthly pages. They are updated every day.
- December 2026: 198 upcoming events, including 8 FDA decision dates and 29 expected clinical data readouts
Biotech Catalyst Lookup
Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.
Automatically generated AI snapshot
Enter a ticker to receive a snapshot generated by artificial intelligence using web sources. Responses are not individually checked by a person before they are displayed.
Dates, events and sources may be incomplete, incorrect or out of date. Check the information against official company releases, SEC filings, FDA documents or ClinicalTrials.gov. Estimated dates are not firm deadlines.
For information and education only. Not investment advice or a recommendation to buy or sell securities.
Read the full disclaimerRecently viewed catalysts
CGONClinical
CG Oncology, Inc. (NASDAQ: CGON)
Late-breaking podium presentation of PIVOT-006 Phase 3 topline results at the Society of Urologic Oncology (SUO) Annual Meeting
2026-12-02
AKBACatalyst
Akebia Therapeutics, Inc. (Nasdaq: AKBA)
End of Vafseo TDAPA reimbursement period and start of the 2027 post-TDAPA add-on payment adjustment
2027-01-01
UNCYPDUFA
Unicycive Therapeutics, Inc. (Nasdaq: UNCY)
FDA decision (PDUFA target action date) on the resubmitted NDA for oxylanthanum carbonate (OLC)
2027-03-25
KPTIPDUFA
Karyopharm Therapeutics Inc. (KPTI; OTC: KPTIQ since November 11, 2026)
FDA decision on supplemental New Drug Application for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis (accelerated approval pathway)
2027-06-28
PRLDClinical
Prelude Therapeutics Incorporated (Nasdaq: PRLD)
Initial proof-of-concept clinical data from the Phase 1 study of PRT13722, a KAT6A oral degrader, in HR+/HER2- breast cancer
2nd half of 2027
SLSRegulatory
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)
Biologics License Application (BLA) submission for galinpepimut-S (GPS) in AML, following a planned FDA meeting on an accelerated filing strategy
First half 2027
SRRKRegulatory
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CHMP opinion on the resubmitted apitegromab Marketing Authorisation Application (MAA) for spinal muscular atrophy (SMA) in the EU
H1 2027
LXEOCatalyst
Lexeo Therapeutics, Inc.
Finalization of the pivotal study design, statistical analysis plan and confirmatory strategy for LX2020 in PKP2 arrhythmogenic cardiomyopathy, subject to FDA discussions
H1 2027
HCMRegulatory
HUTCHMED (CHINA) LIMITED (ticker HCM)
FDA review of the US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer; FDA action date not disclosed
Not available
OLMAClinical
Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.; Nasdaq: OLMA)
Top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant
Q1 2027
IBIOClinical
iBio, Inc.
Interim Phase 1 single-ascending-dose (SAD) data for IBIO-600 in overweight or obese adults
Q1 2027
OCSClinical
Oculis Holding AG (Nasdaq: OCS)
PREDICT-1 registrational topline data for licaminlimab in genotype-selected dry eye disease (company guidance per Merlintrader tracker, not confirmed in an official release)
Year-end 2026



